AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) A compound of the formula:



(I)

wherein

ring A represents a benzene ring, which may have 1 to 3 substituents selected from

(1) halogen atom,

(2) nitro,

(3) cyano,

(4) hydroxy,

(5) C_{1-6} alkyl optionally having 1 to 5 halogen atoms,

(6) C_{6-14} aryl, which may have 1 to 5 substituents selected from halogen atom, hydroxy, C_{1-6} alkyl optionally having 1 to 5 halogen atoms, C_{1-6} alkoxy optionally having 1 to 5 halogen atoms, and C_{1-6} alkyl-carbonyl optionally having 1 to 5 halogen atoms,

(7) C_{1-6} alkoxy optionally having 1 to 5 halogen atoms,

(8) C_{1-6} alkylthio optionally having 1 to 5 halogen atoms,

(9) amino,

(10) mono- or di-C_{1-6} alkylamino,

(11) C_{1-6} alkyl-carboxamide optionally having 1 to 5 halogen atoms,

(12) carbamoyl,

(13) mono- or di-C_{1-6} alkyl-carbamoyl,

(14) C_{1-6} alkyl-carbonyl optionally having 1 to 5 halogen atoms,

(15) C_{1-6} alkyl-sulfonyl optionally having 1 to 5 halogen atoms,

(16) 5- to 7-membered non-aromatic heterocyclic group,

(17) C_{1-6} alkoxy-C_{1-6} alkoxy,

(18) 5- or 6-membered heterocyclic carbonyl,

(19) carboxy,

(20) C_{1-6} alkoxy-carbonyl,

(21) 5- to 7-membered aromatic heterocyclic group, which may have 1 to 3 substituents selected from C_{1-6} alkyl optionally having 1 to 5 halogen atoms,

(22) C_{1-6} alkylsulfinyl optionally having 1 to 5 halogen atoms, and

(23) C_{3-8} cycloalkyl-C_{1-6} alkoxy ~~optionally having substituents~~;

B represents a C_{1-6} alkylene optionally having substituents; Y and Ya are the same or different and each represents a bond, C_{1-6} alkylene, -CO-, -CO-alkb- or -CO-alkd-O- (alkb and alkd are the same or different and each represents a C_{1-6} alkylene or a bond) ~~or a spacer having a main chain of 1 to 6 atoms~~;

R^1 and R^2 are the same or different and each represents a hydrogen atom or C_{1-6} alkyl~~, a hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents~~;

R^3 represents a hydrogen atom~~, a hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents~~;

R^4 and R^5 are the same or different and each represents a hydrogen atom or C_{1-6} alkyl ~~a hydrocarbon group optionally having substituents~~, or R^4 and R^5, together with the adjacent carbon atom, form a ring optionally having substituents;

R^6 represents an indolyl group optionally having substituents;

Z represents piperidinyl optionally having substituents or piperazinyl optionally having substituents; and

Za represents a hydrogen atom, a halogen atom or a cyclic group optionally having substituents; or a salt thereof.

2-3. (Canceled)

4. (Original) The compound according to claim 1, wherein one of R^4 and R^5 is a hydrogen atom, and the other is a C_{1-6} alkyl optionally having substituents.

5-6. (Canceled)

7. (Currently Amended) The compound according to claim 1, wherein Z is piperidinyl or piperazinyl, each of which is substituted by a group of the formula: -Yd-Ara wherein Yd is a bond, C_{1-6} alkylene, -alka-O-alkb-, -alka-S-alkb-, -alka-CO-alkb-, -alka-SO-alkb-, -alka-SO_2-alkb- or -alkc-CO-alkd-NH-alke- (wherein alka, alkb, alkc, alkd and alke are the same or different and each represents a C_{1-6} alkylene or a bond) ~~represents~~

~~a bond or a spacer having a main chain of 1 to 6 atoms~~, and Ara represents a monocyclic group optionally having substituents.

8. (Original) The compound according to claim 1, wherein Ya is a bond, and Za is a hydrogen atom.

9. (Original) The compound according to claim 1, wherein B is a C_{1-6} alkylene.

10. (Canceled)

11. (Original) The compound according to claim 1, wherein R^1 and R^2 are C_{1-6} alkyl.

12. (Original) The compound according to claim 1, wherein Y is -CO-.

13. (Original) The compound according to claim 1, which is

N-((1R,2S)-1-(((5-((dimethylamino)methyl)-2-((methylamino)carbonyl)phenyl)amino)carbonyl)-2-(1H-indol-3-yl)propyl)-4-(2-methylphenyl)-1-piperidinecarboxamide;

N-((1R,2S)-1-(((2-((dimethylamino)carbonyl)-5-((dimethylamino)methyl)phenyl)amino)carbonyl)-2-(1H-indol-3-yl)propyl)-4-(4-fluorophenyl)-1-piperidinecarboxamide;

N-((1R,2S)-1-(((5-((dimethylamino)methyl)-2-methoxyphenyl)amino)carbonyl)-2-(1H-indol-3-yl)propyl)-4-(4-fluoro-2-methylphenyl)-3-oxo-1-piperazinecarboxamide;

N-((1R,2S)-1-(((5-((dimethylamino)methyl)-2-methoxyphenyl)amino)carbonyl)-2-(1H-indol-3-yl)propyl)-4-(2-methylphenyl)-1-piperazinecarboxamide;

N-((1R,2S)-1-(((5-((dimethylamino)methyl)-2-ethoxyphenyl)amino)carbonyl)-2-(1H-indol-3-yl)propyl)-4-(4-fluorophenyl)-1-piperazinecarboxamide; or

N-((1R,2S)-1-(((5-((dimethylamino)methyl)-2-ethoxyphenyl)amino)carbonyl)-2-(1H-indol-3-yl)propyl)-4-phenyl-1-piperidinecarboxamide.

14. (Previously Presented) A pharmaceutical preparation comprising the compound according to claim 1 or a salt thereof.

15. (Original) The pharmaceutical preparation according to claim 14, which is a somatostatin receptor binding inhibitor.

16. (Original) The pharmaceutical preparation according to claim 15, which is a somatostatin subtype 2 receptor binding inhibitor.

17. (Original) The pharmaceutical preparation according to claim 14, which is a somatostatin receptor agonist.

18. (Original) The pharmaceutical preparation according to claim 17, which is a somatostatin subtype 2 receptor agonist.

19. (Currently Amended) The pharmaceutical preparation according to claim 14, which is a prophylactic or therapeutic agent for diabetes type 1 or type 2, diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, Doan syndrome or orthostatic hypotension ~~or diabetic complications~~.

20. (Currently Amended) The pharmaceutical preparation according to claim 14, which is a ~~prophylactic or~~ therapeutic agent for obesity.

21. (Canceled)

22. (Previously Presented) A method for inhibiting somatostatin receptor binding in a mammal, which comprises administering to the mammal an effective amount of the compound according to claim 1 or a salt thereof.

23. (Canceled)

24. (Currently Amended) A method for ~~preventing or~~ treating diabetes type 1 or type 2, diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, Doan syndrome or orthostatic hypotension ~~or diabetic complications~~ in a mammal, which comprises administering to the mammal an effective amount of the compound according to claim 1 or a salt thereof.

25. (Canceled)

26. (Currently Amended) A method for ~~preventing or~~ treating obesity in a mammal, which comprises administering to the mammal an effective amount of the compound according to claim 1 or a salt thereof.

27. (Currently Amended) A method for producing a compound of claim 1 or a salt thereof, which comprises reacting a compound of the formula:



wherein

Y represents a bond, C_{1-6} alkylene, -CO-, -CO-alkb- or -CO-alkd-O- (alkb and alkd are the same or different and each represents a C_{1-6} alkylene or a bond) ~~or a spacer having a main chain of 1 to 6 atoms~~;

R^4 and R^5 are the same or different, and each represents a hydrogen atom or C_{1-6} alkyl ~~a hydrocarbon group optionally having substituents~~, or R^4 and R^5, together with the adjacent carbon atom, form a ring optionally having substituents;

R^6 represents an indolyl group optionally having substituents;

Z represents piperidinyl optionally having substituents or piperazinyl optionally having substituents or a salt thereof, with a compound of the formula:



wherein

ring A represents a benzene ring, which may have 1 to 3 substituents selected from

(1) halogen atom,

(2) nitro,

(3) cyano,

(4) hydroxy,

(5) C_{1-6} alkyl optionally having 1 to 5 halogen atoms,

(6) C_{6-14} aryl, which may have 1 to 5 substituents selected from halogen atom, hydroxy, C_{1-6} alkyl optionally having 1 to 5 halogen atoms, C_{1-6} alkoxy optionally having 1 to 5 halogen atoms, and C_{1-6} alkyl-carbonyl optionally having 1 to 5 halogen atoms,

(7) C_{1-6} alkoxy optionally having 1 to 5 halogen atoms,

(8) C_{1-6} alkylthio optionally having 1 to 5 halogen atoms,

(9) amino,

(10) mono- or di-C_{1-6} alkylamino,

(11) C_{1-6} alkyl-carboxamide optionally having 1 to 5 halogen atoms,

(12) carbamoyl,

(13) mono- or di-C_{1-6} alkyl-carbamoyl,

(14) C_{1-6} alkyl-carbonyl optionally having 1 to 5 halogen atoms,

(15) C_{1-6} alkyl-sulfonyl optionally having 1 to 5 halogen atoms,

(16) 5- to 7-membered non-aromatic heterocyclic group,

(17) C_{1-6} alkoxy-C_{1-6} alkoxy,

(18) 5- or 6-membered heterocyclic carbonyl,

(19) carboxy,

(20) C_{1-6} alkoxy-carbonyl,

(21) 5- to 7-membered aromatic heterocyclic group, which may have 1 to 3 substituents selected from C_{1-6} alkyl optionally having 1 to 5 halogen atoms,

(22) C_{1-6} alkylsulfinyl optionally having 1 to 5 halogen atoms, and

(23) C_{3-8} cycloalkyl-C_{1-6} alkoxy ~~optionally having substituents~~;

B represents a C_{1-6} alkylene optionally having substituents;

R^1 and R^2 are the same or different, and each represents a hydrogen atom or C_{1-6} alkyl~~, a hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents~~;

R^3 represents a hydrogen atom~~, a hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents~~; or a salt thereof to give a compound of the formula:



wherein

each symbol is as defined above; or a salt thereof, and optionally reacting the compound or a salt thereof with a compound of the formula: L^4-Ya-Za wherein L^4 represents a leaving group; Ya represents a bond, C_{1-6} alkylene, -CO-, -CO-alkb- or -CO-alkd-O- (alkb and alkd are the same or different and each represents a C_{1-6} alkylene or a bond) ~~or a spacer having a main chain of 1 to 6 atoms~~; Za represents a hydrogen atom, a halogen atom or a cyclic group optionally having substituents; or a salt thereof.

28. (Canceled)